

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 19	APOLLIT offering free connect time in April 2003
NEWS 28	Mar 20	EVENTLINE will be removed from STN
NEWS 29	Mar 24	PATDPAFULL now available on STN
NEWS 30	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 31	Apr 11	Display formats in DGENE enhanced
NEWS 32	Apr 14	MEDLINE Reload
NEWS 33	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 34	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 35	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),

AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:37:16 ON 21 APR 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:37:26 ON 21 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 APR 2003 HIGHEST RN 503529-60-0

DICTIONARY FILE UPDATES: 20 APR 2003 HIGHEST RN 503529-60-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading C:\Program Files\Stnexp\Queries\10037110.str



chain nodes :

10 11 13 22 33 36 37 38 39 40 46 50 51 52 53 58

ring nodes :

1 2 3 4 5 6 7 8 9 14 15 16 17 18 19 23 24 25 26 27 28 29 30
31 47 48 49

chain bonds :

3-23 7-36 8-46 9-10 10-22 13-17 49-58 52-53

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 14-15 14-19 15-16 16-17 17-18
18-19 23-47 24-25 24-29 24-31 25-26 26-27 27-28 27-30 28-29 30-31 47-48
48-49

exact/norm bonds :

3-23 4-7 5-9 7-8 7-36 8-9 8-46 9-10 10-22 13-17 23-47 24-25 24-29
24-31 25-26 26-27 27-28 27-30 28-29 30-31 47-48 48-49 49-58

exact bonds :

52-53

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19

G1:[*1],[*2]

G3:[*3],[*4]

<10/037,110, claim 1>Page 4

G4:[*5],[*6],[*7],[*8]

G5:[*9],[*10],[*11]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 22:Atom
23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom
33:Atom 36:Atom 37:CLASS 38:CLASS 39:CLASS 40:CLASS 46:CLASS 47:Atom
48:Atom 49:Atom 50:CLASS 51:CLASS 52:CLASS 53:CLASS 58:CLASS

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 16:37:49 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 35 TO ITERATE

100.0% PROCESSED 35 ITERATIONS

19 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 346 TO 1054

PROJECTED ANSWERS: 119 TO 641


L2 19 SEA SSS SAM L1

=> d scan

L2 19 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 1H-Indole, 1-(2-dibenzofuranylsulfonyl)-4-(1-piperazinyl)- (9CI)


MF C24 H21 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 19 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 1H-Indole, 1-[(5-chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]-4-(1-
piperazinyl)- (9CI)
MF C18 H16 Cl N5 O3 S
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 19 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 1H-Indole, 1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI)

MF C18 H18 Cl N3 O2 S . Cl H




● HCl

L2 19 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]-. (9CI)

MF C28 H26 Cl N3 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6

L2 19 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 1H-Indole, 5-chloro-1-(2-naphthalenylsulfonyl)-4-(1-piperazinyl)- (9CI)

MF C22 H20 Cl N3 O2 S

CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 19 ANSWERS REGISTRY COPYRIGHT 2003 ACS


IN 1H-Indole, 1-[(2-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI)

MF C19 H18 N4 O2 S . C2 H F3 O2

CM 1




CM 2



L2 19 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Benzamide, N-[[5-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-2-thienyl]methyl]-, monohydrochloride (9CI)

MF C24 H24 N4 O3 S2 . Cl H




● HCl

L2 19 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 1H-Indole, 7-chloro-1-[(3-chlorophenyl)sulfonyl]-4-(hexahydro-1H-1,4-diazepin-1-yl)-, monohydrochloride (9CI).

MF C19 H19 Cl2 N3 O2 S . Cl H




L2 19 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 1H-Indole, 5-chloro-1-[(3,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-
(9CI)

MF C18 H16 Cl3 N3 O2 S

CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 19 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Benzoic acid, 2-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-, methyl ester
(9CI)

MF C20 H21 N3 O4 S

CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

<10/037,110, claim 1>Page 15

=> s ll full

FULL SEARCH INITIATED 16:40:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 586 TO ITERATE

100.0% PROCESSED 586 ITERATIONS

313 ANSWERS

SEARCH TIME: 00.00.01


L3 313 SEA SSS FUL L1

=> d scan

L3 313 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 1H-Indole, 1-[(4-bromo-2-cyanophenyl)sulfonyl]-5-chloro-4-(1-piperazinyl)-
, monohydrochloride (9CI)

MF C19 H16 Br Cl N4 O2 S . Cl H



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

150.55

150.76

FILE 'CAPLUS' ENTERED AT 16:41:49 ON 21 APR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Apr 2003 VOL 138 ISS 17

FILE LAST UPDATED: 20 Apr 2003 (20030420/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4

5 L3

=> sort py l4

SORT ENTIRE ANSWER SET? (Y)/N:.

PROCESSING COMPLETED FOR L4

L5


5 SORT L4 PY

=> d 1-5 cbib pi fhitr

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS

2002:977788 Document No. 138:55865 Preparation of 4-piperazinylindoles with 5-HT6 receptor affinity. (Briggs,) Andrew John; Clark, Robin Douglas; Harris, Ralph New, III; Repke, David Bruce; Wren, Douglas Leslie (F. Hoffmann-La Roche AG, Switz.). PCT Int. Appl. WO 2002102774 A1 20021227, 50 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-EP6201 20020606. PRIORITY: US 2001-PV298834 20010615; US 2002-PV378748 20020508.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002102774	A1	20021227	WO 2002-EP6201	20020606
	W:				
					AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
	RW:				GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
	US 2003045527	A1	20030306	US 2002-172360	20020614
IT	393508-47-9P				
	RL:				PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
					(preparation of 4-piperazinylindoles with 5-HT6 receptor affinity)
RN	393508-47-9	CAPLUS			
CN	1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI)				(CA INDEX NAME)




● HCl

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS

2002:408522 Document No. 136:401783 Preparation of 4-piperazinoindoles for treating CNS disorders. Bromidge, Steven Mark (Smithkline Beecham P.L.C., UK). PCT Int. Appl. WO 2002041889 A2 20020530, 44 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-EP13411 20011116. PRIORITY: GB 2000-28708 20001124; GB 2001-13517 20010604. PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2002041889 A2 20020530 WO 2001-EP13411 20011116
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002020715 A5 20020603 AU 2002-20715 20011116

IT 412048-92-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-piperazinoindoles for treating CNS disorders)
RN 412048-92-1 CAPLUS
CN 1H-Indole, 1-[(4-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS

2002:353426 Document No. 136:369738 Preparation of 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands.

Kelly, Michael Gerard; Cole, Derek Cecil (American Home Products Corporation, USA). PCT Int. Appl. WO 2002036562 A2 20020510, 63 pp.

DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US45389 20011031. PRIORITY: US 2000-PV245118-20001102.

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2002036562 A2 20020510 WO 2001-US45389 20011031
WO 2002036562 A3 20030123

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


AU 2002020051 A5 20020515 AU 2002-20051 20011031
US 2002115670 A1 20020822 US 2001-3015 20011101

IT 412049-71-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands)

RN 412049-71-9 CAPLUS


CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS

2002:314905 Document No. 136:309847 2-, 3-, 4-, or 5-substituted-1-(benzenesulfonyl)indoles and their use in therapy. Caldirola, Patrizia; Johansson, Gary; Nilsson, Bjoern M. (Biovitrum AB, Swed.). PCT Int. Appl. WO 2002032863 A1 20020425, 79 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-SE2319 20011019. PRIORITY: SE 2000-3810 20001020; US 2000-PV243115 20001025.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032863	A1	20020425	WO 2001-SE2319	20011019
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2001096193	A5	20020429	AU 2001-96193	20011019
	US 2002165251	A1	20021107	US 2001-37110	20011022
IT	393508-47-9P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of antiobesity benzenesulfonylindoles)				
RN	393508-47-9 CAPLUS				
CN	1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI)				
	(CA INDEX NAME)				



● HCl

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS


2002:89998 Document No. 136:129087 New combination of serotonin 5-HT_{2c} agonist and 5-HT₆ antagonist as pharmaceutical formulation, and therapeutic uses. Jossan, Sukhwinder; Nilsson, Bjorn M.; Sakariassen, Kjell S.; Svartengren, Jan (Biovitrum AB, Swed.). PCT Int. Appl. WO 2002008178 A1 20020131, 24 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-SE1651 20010719. PRIORITY: SE 2000-2754 20000721. PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2002008178	A1	20020131	WO 2001-SE1651	20010719
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1301476	A1	20030416	EP 2001-961472	20010719
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2002068732	A1	20020606	US 2001-908801	20010720

IT 393508-47-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(serotonin 5-HT_{2c} agonist-5-HT₆ antagonist combination pharmaceutical, and therapeutic uses)

RN 393508-47-9 CAPLUS

CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI)
(CA INDEX NAME)



HCl

<10/037,110, claim 1>Page 24

=> d 1-3 ti hitstr

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS

TI Preparation of 4-piperazinyllindoles with 5-HT6 receptor affinity

IT 393508-47-9P 412048-52-3P 412048-56-7P

412048-93-2P 412048-95-4P 412048-98-7P

412049-05-9P 412049-61-7P 412049-71-9P

412049-72-0P 423175-42-2P 431043-51-5P

431043-52-6P 431043-57-1P 431043-60-6P

431043-89-9P 431043-91-3P 431043-92-4P

431044-30-3P 431044-64-3P 431044-65-4P

431044-66-5P 431044-67-6P 431045-30-6P

431045-35-1P 431045-37-3P 431045-39-5P

431045-41-9P 431045-42-0P 479080-52-9P

479080-53-0P 479080-54-1P 479080-55-2P

479080-56-3P 479080-57-4P 479080-58-5P

479080-62-1P 479080-66-5P 479080-67-6P

479080-68-7P 479080-69-8P 479080-70-1P

479080-74-5P 479080-75-6P 479080-76-7P

479080-77-8P 479080-78-9P 479080-79-0P

479080-80-3P 479080-81-4P 479080-82-5P

479080-83-6P 479080-84-7P 479080-85-8P

479080-86-9P 479080-87-0P 479081-01-1P


479081-03-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-piperazinyllindoles with 5-HT6 receptor affinity)

RN 393508-47-9 CAPLUS


CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-52-3 CAPLUS


CN 1H-Indole, 1-(1-naphthalenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-56-7 CAPLUS


CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 412048-93-2 CAPLUS

CN 1H-Indole, 1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA
INDEX NAME)




RN 412048-95-4 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-
(9CI) (CA INDEX NAME)




RN 412048-98-7 CAPLUS

CN 1H-Indole, 1-[(3-cyanophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX
NAME)




RN 412049-05-9 CAPLUS

CN 1H-Indole, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1-piperazinyl)-
(9CI) (CA INDEX NAME)




RN 412049-61-7 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 412049-71-9 CAPLUS
CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 412049-72-0 CAPLUS
CN 1H-Indole, 1-[(2,5-dimethoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 423175-42-2 CAPLUS
CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 431043-51-5 CAPLUS

CN 1H-Indole, 1-[(2,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431043-52-6 CAPLUS

CN 1H-Indole, 1-[(2,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431043-51-5

CMF C18 H17 Cl2 N3 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 431043-57-1 CAPLUS
CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 431043-60-6 CAPLUS
CN 1H-Indole, 1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 412048-93-2
CMF C18 H18 Cl N3 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 431043-89-9 CAPLUS

CN 1H-Indole, 1-[(2-fluorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 431043-91-3 CAPLUS

CN 1H-Indole, 1-[(3-fluorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431043-92-4 CAPLUS

CN 1H-Indole, 1-[(3-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-91-3


CMF C18 H18 F N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-30-3 CAPLUS

CN 1H-Indole, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 412049-05-9


CMF C16 H19 N5 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 431044-64-3 CAPLUS

CN 1H-Indole, 1-[(3-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431044-65-4 CAPLUS

CN 1H-Indole, 1-[(3-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-64-3


CMF C19 H21 N3 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 431044-66-5 CAPLUS

CN 1H-Indole, 1-[(2,6-difluorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431044-67-6 CAPLUS

CN 1H-Indole, 1-[(2,6-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-66-5


CMF C18 H17 F2 N3 O2 S




CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 431045-30-6 CAPLUS
CN 1H-Indole, 1-[(3-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 431045-35-1 CAPLUS
CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-37-3 CAPLUS
CN 1H-Indole, 1-(1-naphthalenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-39-5 CAPLUS

CN 1H-Indole, 1-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4-(1-piperazinyl)-
(9CI) (CA INDEX NAME)




RN 431045-41-9 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 431045-42-0 CAPLUS

CN 1H-Indole, 1-[(3,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA
INDEX NAME)



RN 479080-52-9 CAPLUS


CN 1H-Indole, 1-[(3,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 479080-53-0 CAPLUS


CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
dihydrochloride (9CI) (CA INDEX NAME)



2 HCl

RN 479080-54-1 CAPLUS

CN 1H-Indole, 1-[(3-bromophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 479080-55-2 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-(2-thienylsulfonyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431045-41-9


CMF C16 H17 N3 O2 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 479080-56-3 CAPLUS

CN 1H-Indole, 1-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431045-39-5


CMF C22 H27 N3 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 479080-57-4 CAPLUS

CN 1H-Indole, 1-[[4-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 479080-58-5 CAPLUS


CN 1H-Indole, 1-[[4-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)-,

mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 479080-57-4


CMF C19 H21 N3 O4 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 479080-62-1 CAPLUS

CN 1H-Indole, 1-[(2,5-dimethoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 412049-72-0


CMF C20 H23 N3 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 479080-66-5 CAPLUS

CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431045-35-1


CMF C18 H18 Cl N3 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 479080-67-6 CAPLUS


CN 1H-Indole, 1-[[3-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 479080-68-7 CAPLUS
 CN 1H-Indole, 1-[[3-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 479080-67-6
 CMF C19 H21 N3 O4 S2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 479080-69-8 CAPLUS
 CN 1H-Indole, 1-[[3-bromo-5-(methylsulfonyl)phenyl]sulfonyl]-4-(1-
 piperazinyl)- (9CI) (CA INDEX NAME)




RN 479080-70-1 CAPLUS

CN 1H-Indole, 1-[[3-bromo-5-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 479080-69-8


CMF C19 H20 Br N3 O4 S2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 479080-74-5 CAPLUS

CN 1H-Indole, 1-[(5-bromo-6-chloro-3-pyridinyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 479080-75-6 CAPLUS

CN 1H-Indole, 1-[(5-bromo-6-chloro-3-pyridinyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 479080-74-5


CMF C17 H16 Br Cl N4 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 479080-76-7 CAPLUS

CN Benzenesulfonamide, N,N-dimethyl-3-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 479080-77-8 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-3-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 479080-78-9 CAPLUS

CN 1H-Indole, 1-[[2-fluoro-5-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 479080-79-0 CAPLUS

CN 1H-Indole, 1-[[2-fluoro-5-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 479080-78-9
CMF C19 H20 F N3 O4 S2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 479080-80-3 CAPLUS
CN 1H-Indole, 1-[(3-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 412048-98-7
CMF C19 H18 N4 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 479080-81-4 CAPLUS

CN 1H-Indole, 1-[[2-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)- (9CI)
(CA INDEX NAME)




RN 479080-82-5 CAPLUS

CN 1H-Indole, 1-[[2-(methylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 479080-81-4


CMF C19 H21 N3 O4 S2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 479080-83-6 CAPLUS

CN 1H-Indole, 1-[[2-[(2-methylpropyl)sulfonyl]phenyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 479080-84-7 CAPLUS

CN 1H-Indole, 1-[[2-[(2-methylpropyl)sulfonyl]phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 479080-83-6


CMF C22 H27 N3 O4 S2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 479080-85-8 CAPLUS


CN 1H-Indole, 1-[[3-(ethylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 479080-86-9 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[3-(propylsulfonyl)phenyl]sulfonyl]- (9CI)
(CA INDEX NAME)




RN 479080-87-0 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[3-(propylsulfonyl)phenyl]sulfonyl]-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 479080-86-9


CMF C21 H25 N3 O4 S2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 479081-01-1 CAPLUS

CN 1H-Indole, 1-[[[3-(ethylsulfonyl)phenyl]sulfonyl]-4-(1-piperazinyl)- (9CI)
(CA INDEX NAME)



RN 479081-03-3 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[[3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




IT 479080-94-9P 479080-95-0P 479080-96-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-piperazinylindoles with 5-HT6 receptor affinity)


RN 479080-94-9 CAPLUS

CN 1H-Indole, 1-[(3,5-dichlorophenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 479080-95-0 CAPLUS

CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 479080-96-1 CAPLUS

CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS

TI Preparation of 4-piperazinoindoles for treating CNS disorders

IT 412048-92-1P 412048-95-4P 412048-98-7P

412049-71-9P 431043-42-4P 431043-43-5P

431043-45-7P 431043-47-9P 431043-49-1P

431043-52-6P 431043-55-9P 431043-58-2P

431043-60-6P 431043-63-9P 431043-66-2P

431043-68-4P 431043-71-9P 431043-73-1P

431043-75-3P 431043-77-5P 431043-79-7P

431043-81-1P 431043-83-3P 431043-86-6P

431043-88-8P 431043-90-2P 431043-92-4P

431043-95-7P 431043-98-0P 431044-01-8P

431044-03-0P 431044-04-1P 431044-06-3P

431044-08-5P 431044-09-6P 431044-11-0P

431044-13-2P 431044-15-4P 431044-17-6P

431044-19-8P 431044-21-2P 431044-23-4P

431044-25-6P 431044-27-8P 431044-29-0P

431044-30-3P 431044-32-5P 431044-34-7P

431044-36-9P 431044-38-1P 431044-39-2P

431044-41-6P 431044-43-8P 431044-45-0P

431044-47-2P 431044-49-4P 431044-50-7P

431044-51-8P 431044-53-0P 431044-55-2P

431044-57-4P 431044-59-6P 431044-61-0P

431044-63-2P 431044-65-4P 431044-67-6P

431044-69-8P 431044-71-2P 431044-72-3P

431044-74-5P 431044-76-7P 431044-78-9P

431044-80-3P 431044-82-5P 431044-84-7P

431044-86-9P 431044-87-0P 431044-89-2P

431044-91-6P 431044-93-8P 431044-95-0P

431044-97-2P 431044-99-4P 431045-01-1P

431045-03-3P 431045-29-3P 431045-30-6P

431045-31-7P 431045-32-8P 431045-33-9P

431045-35-1P 431045-36-2P 431045-37-3P

431045-38-4P 431045-39-5P 431045-40-8P

431045-41-9P 431045-42-0P 431045-43-1P

431045-44-2P 431045-45-3P 431045-46-4P

431045-47-5P 431045-48-6P 431045-49-7P

431045-50-0P 431045-51-1P 431045-52-2P

431045-53-3P 431045-54-4P 431045-55-5P

431045-56-6P 431045-57-7P 431045-58-8P

431045-59-9P 431045-60-2P 431045-61-3P

431045-62-4P 431045-63-5P 431045-64-6P

431045-65-7P 431045-66-8P 431045-67-9P

431045-68-0P 431045-69-1P 431045-71-5P

431045-72-6P 431045-73-7P 431045-74-8P

431045-75-9P 431045-76-0P 431045-78-2P

431045-79-3P 431045-80-6P 431045-81-7P

431045-82-8P 431045-83-9P 431045-85-1P

431045-87-3P 431045-88-4P 431045-89-5P

431045-90-8P 431045-91-9P 431045-92-0P


431045-93-1P 431045-94-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 4-piperazinoindoles for treating CNS disorders)


RN 412048-92-1 CAPLUS

CN 1H-Indole, 1-[(4-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX
NAME)




RN 412048-95-4 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-
(9CI) (CA INDEX NAME)




RN 412048-98-7 CAPLUS

CN 1H-Indole, 1-[(3-cyanophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX
NAME)




RN 412049-71-9 CAPLUS

CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 431043-42-4 CAPLUS

CN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431043-43-5 CAPLUS

CN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-4-(1-piperazinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 431043-42-4


CMF C21 H20 Cl N3 O2 S2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 431043-45-7 CAPLUS

CN Acetamide, N-[4-methyl-5-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-2-thiazolyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-44-6


CMF C18 H21 N5 O3 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431043-47-9 CAPLUS

CN 1H-Indole, 1-[(pentafluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-46-8


CMF C18 H14 F5 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431043-49-1 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[(2,4,5-trichlorophenyl)sulfonyl]-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-48-0


CMF C18 H16 Cl3 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431043-52-6 CAPLUS

CN 1H-Indole, 1-[(2,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-51-5


CMF C18 H17 Cl2 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431043-55-9 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[(2,4,6-trimethylphenyl)sulfonyl]-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-54-8


CMF C21 H25 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431043-58-2 CAPLUS

CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-57-1


CMF C18 H18 F N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431043-60-6 CAPLUS

CN 1H-Indole, 1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 412048-93-2


CMF C18 H18 Cl N3 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 431043-63-9 CAPLUS
CN 1H-Indole, 1-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431043-62-8
CMF C18 H17 Cl N4 O4 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431043-66-2 CAPLUS
CN 1H-Indole, 1-[(4-iodophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431043-65-1
CMF C18 H18 I N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431043-68-4 CAPLUS

CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 423175-42-2


CMF C19 H21 N3 O3 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 431043-71-9 CAPLUS
CN 1H-Indole, 1-[(4-methylphenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431043-70-8
CMF C19 H21 N3 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431043-73-1 CAPLUS
CN Benzoic acid, 2-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-, methyl
ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431043-72-0
CMF C20 H21 N3 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431043-75-3 CAPLUS

CN 1H-Indole, 1-[(2,5-dimethylphenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-74-2


CMF C20 H23 N3 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 431043-77-5 CAPLUS
CN Benzoic acid, 3-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431043-76-4
CMF C19 H19 N3 O4 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431043-79-7 CAPLUS
CN 1H-Indole, 1-[(3,4-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431043-78-6
CMF C18 H17 Cl2 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431043-81-1 CAPLUS

CN 1H-Indole, 1-[(4,5-dibromo-2-thienyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-80-0


CMF C16 H15 Br2 N3 O2 S2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 431043-83-3 CAPLUS
CN 1H-Indole, 1-[(4-ethylphenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431043-82-2
CMF C20 H23 N3 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431043-86-6 CAPLUS
CN 1H-Indole, 4-(1-piperazinyl)-1-[(4-propylphenyl)sulfonyl]-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431043-85-5
CMF C21 H25 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431043-88-8 CAPLUS

CN 1H-Indole, 1-[(4-bromo-2,5-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-87-7


CMF C18 H16 Br F2 N3 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 431043-90-2 CAPLUS
CN 1H-Indole, 1-[(2-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431043-89-9
CMF C18 H18 F N3 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431043-92-4 CAPLUS
CN 1H-Indole, 1-[(3-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431043-91-3
CMF C18 H18 F N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431043-95-7 CAPLUS

CN 1H-Indole, 1-[(2,4-dichloro-5-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431043-94-6


CMF C19 H19 Cl2 N3 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 431043-98-0 CAPLUS
CN 1H-Indole, 1-[(2-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431043-97-9
CMF C18 H18 Cl N3 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431044-01-8 CAPLUS
CN 1H-Indole, 1-[(3-methylphenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431044-00-7
CMF C19 H21 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-03-0 CAPLUS

CN 1H-Indole, 1-[(2,3-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-02-9


CMF C18 H17 Cl2 N3 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 431044-04-1 CAPLUS
CN 1H-Indole, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 423175-41-1
CMF C16 H15 Cl2 N3 O2 S2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431044-06-3 CAPLUS
CN 1H-Indole, 1-[(3-bromo-5-chloro-2-thienyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431044-05-2
CMF C16 H15 Br Cl N3 O2 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-08-5 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[5-(2-pyridinyl)-2-thienyl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-07-4


CMF C21 H20 N4 O2 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-09-6 CAPLUS

CN 1H-Indole, 1-[(4-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 412048-96-5


CMF C19 H18 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-11-0 CAPLUS

CN 1H-Indole, 1-[(2-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-10-9


CMF C19 H18 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-13-2 CAPLUS

CN 1H-Indole, 1-[(4-butoxyphenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-12-1


CMF C22 H27 N3 O3 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 431044-15-4 CAPLUS
CN 1H-Indole, 1-[(3,6-dibromo-2,5-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431044-14-3
CMF C18 H15 Br2 F2 N3 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431044-17-6 CAPLUS
CN 1H-Indole, 1-[(3-chloro-1,5-dimethyl-1H-pyrazol-4-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431044-16-5
CMF C17 H20 Cl N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-19-8 CAPLUS

CN 1H-Indole, 1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-18-7


CMF C17 H20 N4 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-21-2 CAPLUS

CN 1H-Indole, 1-[[2,5-bis(2,2,2-trifluoroethoxy)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-20-1


CMF C22 H21 F6 N3 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-23-4 CAPLUS

CN 1H-Indole, 1-[(5-fluoro-2-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-22-3


CMF C19 H20 F N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-25-6 CAPLUS

CN 1H-Indole, 1-[(5-chloro-2-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-24-5


CMF C19 H20 Cl N3 O3 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 431044-27-8 CAPLUS
CN 1H-Indole, 1-[(2,5-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431044-26-7
CMF C18 H17 F2 N3 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431044-29-0 CAPLUS
CN 1H-Indole, 1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431044-28-9
CMF C18 H17 N5 O2 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-30-3 CAPLUS

CN 1H-Indole, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 412049-05-9


CMF C16 H19 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-32-5 CAPLUS

CN 1H-Indole, 1-(2,1,3-benzoxadiazol-4-ylsulfonyl)-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-31-4


CMF C18 H17 N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-34-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[4-(1-piperazinyl)-1H-indol-1-yl]sulfonyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-33-6


CMF C18 H19 N3 O4 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-36-9 CAPLUS

CN 1H-Indole, 1-[[5-(3-isoxazolyl)-2-thienyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-35-8


CMF C19 H18 N4 O3 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-38-1 CAPLUS

CN 1H-Indole, 1-([1,1'-biphenyl]-4-ylsulfonyl)-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-37-0


CMF C24 H23 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-39-2 CAPLUS

CN 1H-Indole, 1-[(5-bromo-2-thienyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 423175-40-0
CMF C16 H16 Br N3 O2 S2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431044-41-6 CAPLUS
CN 1H-Indole, 1-[(3,4-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431044-40-5
CMF C18 H17 F2 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-43-8 CAPLUS

CN 1H-Indole, 1-[(4-butylphenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-42-7


CMF C22 H27 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-45-0 CAPLUS

CN 1H-Indole, 1-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-44-9


CMF C19 H17 Br F3 N3 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-47-2 CAPLUS

CN 1H-Indole, 1-[(5-chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-46-1


CMF C18 H16 Cl N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-49-4 CAPLUS

CN 1H-Indole, 1-[(4-bromo-2-ethylphenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-48-3


CMF C20 H22 Br N3 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 431044-50-7 CAPLUS

CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431044-51-8 CAPLUS

CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-50-7


CMF C17 H16 Cl N5 O2 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-53-0 CAPLUS

CN 1H-Indole, 1-[(4-bromo-2-methylphenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-52-9


CMF C19 H20 Br N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-55-2 CAPLUS

CN 1H-Indole, 1-[[2,6-dichloro-4-(trifluoromethyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-54-1


CMF C19 H16 Cl2 F3 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-57-4 CAPLUS

CN 1H-Indole, 1-(5-isoquinolinylsulfonyl)-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-56-3


CMF C21 H20 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-59-6 CAPLUS

CN 1H-Indole, 1-[(4-acetylphenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-58-5


CMF C20 H21 N3 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-61-0 CAPLUS

CN 1H-Indole, 1-[(2-iodophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-60-9


CMF C18 H18 I N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-63-2 CAPLUS

CN 1H-Indole, 1-[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-62-1


CMF C17 H21 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-65-4 CAPLUS

CN 1H-Indole, 1-[(3-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431044-64-3
CMF C19 H21 N3 O3 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431044-67-6 CAPLUS
CN 1H-Indole, 1-[(2,6-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431044-66-5
CMF C18 H17 F2 N3 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431044-69-8 CAPLUS
CN 1H-Indole, 4-(1-piperazinyl)-1-[[2-(trifluoromethoxy)phenyl]sulfonyl]-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431044-68-7
CMF C19 H18 F3 N3 O3 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431044-71-2 CAPLUS
CN 1H-Indole, 1-[(2-nitrophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431044-70-1
CMF C18 H18 N4 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-72-3 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[4-(trifluoromethoxy)phenyl]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 412049-03-7


CMF C19 H18 F3 N3 O3 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 431044-74-5 CAPLUS
CN 1H-Indole, 1-[(2,4-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431044-73-4
CMF C18 H17 F2 N3 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431044-76-7 CAPLUS
CN 1H-Indole, 1-[(5,7-dichloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 431044-75-6
CMF C21 H19 Cl2 N3 O2 S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-78-9 CAPLUS

CN 1H-Indole, 1-[(5-chloro-2-methylbenzo[b]thien-3-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-77-8


CMF C21 H20 Cl N3 O2 S2



CM .2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-80-3 CAPLUS

CN 1H-Indole, 1-[(5-chloro-3-methyl-2-benzofuranyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-79-0


CMF C21 H20 Cl N3 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-82-5 CAPLUS

CN 1H-Indole, 1-[(2-chloro-6-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431044-81-4
CMF C19 H20 Cl N3 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431044-84-7 CAPLUS
CN 1H-Indole, 1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431044-83-6
CMF C20 H17 F6 N3 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431044-86-9 CAPLUS
CN 1H-Indole, 1-[(2,6-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 431044-85-8
CMF C18 H17 Cl2 N3 O2 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 431044-87-0 CAPLUS
CN 1H-Indole, 1-[(7-chloro-2,1,3-benzoxadiazol-4-yl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 412048-97-6
CMF C18 H16 Cl N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-89-2 CAPLUS

CN 1H-Indole, 1-[(3-chloro-5-fluoro-2-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-88-1


CMF C19 H19 Cl F N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-91-6 CAPLUS

CN 1H-Indole, 1-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-90-5


CMF C24 H26 N4 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-93-8 CAPLUS

CN 1H-Indole, 5-chloro-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-92-7


CMF C18 H17 Cl2 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-95-0 CAPLUS

CN 1H-Indole, 5-chloro-1-[(3,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-94-9


CMF C18 H16 Cl3 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-97-2 CAPLUS

CN 1H-Indole, 5-chloro-1-[(2,6-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-96-1


CMF C18 H16 Cl3 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431044-99-4 CAPLUS

CN 1H-Indole, 5-chloro-1-(2-naphthalenylsulfonyl)-4-(1-piperazinyl)-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431044-98-3


CMF C22 H20 Cl N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 431045-01-1 CAPLUS

CN 1H-Indole, 5-chloro-1-[(3,5-dichloro-2-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 431045-00-0


CMF C19 H18 Cl3 N3 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 431045-03-3 CAPLUS

CN 1H-Indole, 5-methoxy-1-[(4-methylphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI)
(CA INDEX NAME)




RN 431045-29-3 CAPLUS

CN 1H-Indole, 1-[(5-chloro-2-naphthalenyl)sulfonyl]-4-(1-piperazinyl)- (9CI)
(CA INDEX NAME)




RN 431045-30-6 CAPLUS

CN 1H-Indole, 1-[(3-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-31-7 CAPLUS

CN 1H-Indole, 1-[(2,5-dichloro-3-thienyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-32-8 CAPLUS


CN 1H-Indole, 1-[(4-chloro-2,5-dimethylphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-33-9 CAPLUS
CN 1H-Indole, 1-[(5-chloro-1-naphthalenyl)sulfonyl]-4-(1-piperazinyl)- (9CI)
(CA INDEX NAME)



RN 431045-35-1 CAPLUS
CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA
INDEX NAME)




RN 431045-36-2 CAPLUS
CN 1H-Indole, 1-[(3-chloro-4-methylphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI)
(CA INDEX NAME)




RN 431045-37-3 CAPLUS

CN 1H-Indole, 1-(1-naphthalenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-38-4 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 431045-39-5 CAPLUS


CN 1H-Indole, 1-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-40-8 CAPLUS
CN 1H-Indole, 1-[(3-nitrophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 431045-41-9 CAPLUS
CN 1H-Indole, 4-(1-piperazinyl)-1-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 431045-42-0 CAPLUS
CN 1H-Indole, 1-[(3,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-43-1 CAPLUS

CN 1H-Indole, 1-[(3-chloro-4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI)
(CA INDEX NAME)




RN 431045-44-2 CAPLUS

CN 1H-Indole, 1-(2-dibenzofuranylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA
INDEX NAME)




RN 431045-45-3 CAPLUS

CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX
NAME)




RN 431045-46-4 CAPLUS

CN 1H-Indole, 1-[(3-chloro-2-methylphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI)
(CA INDEX NAME)




RN 431045-47-5 CAPLUS

CN 1H-Indole, 1-(2-naphthalenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 431045-48-6 CAPLUS


CN 1H-Indole, 1-[(3,5-dichloro-2-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)-
(9CI) (CA INDEX NAME)



RN 431045-49-7 CAPLUS
CN 1H-Indole, 4-((1-piperazinyl)-1-[(2,3,5-trichlorophenyl)sulfonyl]- (9CI)
(CA INDEX NAME)




RN 431045-50-0 CAPLUS
CN 1H-Indole, 1-[(2-chloro-3,5-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-
(9CI) (CA INDEX NAME)



RN 431045-51-1 CAPLUS
CN 1H-Indole, 5-chloro-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,


monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-52-2 CAPLUS


CN 1H-Indole, 4-(1-piperazinyl)-1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-53-3 CAPLUS


CN 1H-Indole, 1-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-54-4 CAPLUS


CN 1H-Indole, 5-chloro-1-(phenylsulfonyl)-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-55-5 CAPLUS

CN 1H-Indole, 5-chloro-1-[(2,6-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-56-6 CAPLUS
CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-5-chloro-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-57-7 CAPLUS
CN 1H-Indole, 5-chloro-1-[(2-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-58-8 CAPLUS
CN 1H-Indole, 5-chloro-4-(1-piperazinyl)-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-59-9 CAPLUS
CN 1H-Indole, 5-chloro-1-[(3-methylphenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-60-2 CAPLUS
CN 1H-Indole, 1-[(3-bromophenyl)sulfonyl]-5-chloro-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-61-3 CAPLUS
CN 1H-Indole, 1-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-5-chloro-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-62-4 CAPLUS
CN 1H-Indole, 5-chloro-1-[(3-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-63-5 CAPLUS
CN 1H-Indole, 5-chloro-1-(1-naphthalenylsulfonyl)-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-64-6 CAPLUS


CN 1H-Indole, 5-chloro-1-[(2,5-difluorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-65-7 CAPLUS


CN 1H-Indole, 5-chloro-1-[(4-fluorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-66-8 CAPLUS


CN 1H-Indole, 5-chloro-1-[(4-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-67-9 CAPLUS

CN 1H-Indole, 5-chloro-4-(1-piperazinyl)-1-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-68-0 CAPLUS
CN 1H-Indole, 5-chloro-4-(1-piperazinyl)-1-(2-pyridinylsulfonyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-69-1 CAPLUS
CN 1H-Indole, 5-chloro-1-[(2,5-dimethylphenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-71-5 CAPLUS


CN 1H-Indole, 7-chloro-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-72-6 CAPLUS


CN 1H-Indole, 7-chloro-1-[(3,5-dichlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-73-7 CAPLUS


CN 1H-Indole, 7-chloro-1-(phenylsulfonyl)-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-74-8 CAPLUS


CN 1H-Indole, 1-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-7-chloro-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-75-9 CAPLUS


CN 1H-Indole, 7-bromo-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-76-0 CAPLUS


CN 1H-Indole-7-carbonitrile, 1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-78-2 CAPLUS


CN 1H-Indole, 5,7-dichloro-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-79-3 CAPLUS

CN 1H-Indole, 5-chloro-1-[(3-chlorophenyl)sulfonyl]-4-(hexahydro-1H-1,4-diazepin-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-80-6 CAPLUS

CN 1H-Indole, 5-chloro-1-[(3-chlorophenyl)sulfonyl]-4-[(3R)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 431045-81-7 CAPLUS


CN 1H-Indole, 5-chloro-1-[(3-chlorophenyl)sulfonyl]-4-[(3S)-3-methyl-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431045-82-8 CAPLUS


CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-5-fluoro-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-83-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-85-1 CAPLUS
CN 1H-Indole, 6-chloro-1-[(3-chlorophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-87-3 CAPLUS
CN 1H-Indole, 1-[[4-chloro-2-(trifluoromethoxy)phenyl]sulfonyl]-4-(1-
piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-88-4 CAPLUS


CN 1H-Indole, 5-chloro-1-[[4-chloro-2-(trifluoromethoxy)phenyl]sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-89-5 CAPLUS


CN 1H-Indole, 1-[(4-bromo-2-cyanophenyl)sulfonyl]-5-chloro-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-90-8 CAPLUS


CN 1H-Indole, 1-[(4-bromo-2-cyanophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-91-9 CAPLUS

CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-5-methoxy-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 431045-92-0 CAPLUS
CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-7-methoxy-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 431045-93-1 CAPLUS
CN 1H-Indole, 1-[(3-chlorophenyl)sulfonyl]-4-(hexahydro-1H-1,4-diazepin-1-yl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 431045-94-2 CAPLUS

CN 1H-Indole, 7-chloro-1-[(3-chlorophenyl)sulfonyl]-4-(hexahydro-1H-1,4-diazepin-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 431045-95-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-piperazinoindoles for treating CNS disorders)

RN 431045-95-3 CAPLUS

CN 1H-Indole, 1-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS


TI Preparation of 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands

IT **412049-71-9P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands)

RN 412049-71-9 CAPLUS

CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



IT **393508-47-9P 412048-59-0P 412048-92-1P**

412049-03-7P 423174-01-0P 423174-03-2P

423174-05-4P 423174-17-8P 423174-25-8P

423174-33-8P 423174-41-8P 423174-48-5P


423175-40-0P 423175-41-1P 423175-42-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands)

RN 393508-47-9 CAPLUS


CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 412048-59-0 CAPLUS


CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 412048-92-1 CAPLUS


CN 1H-Indole, 1-[(4-bromophenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



Thomas McKenzie 04/21/2003


RN 412049-03-7 CAPLUS

CN 1H-Indole, 4-(1-piperazinyl)-1-[[4-(trifluoromethoxy)phenyl]sulfonyl]-
(9CI) (CA INDEX NAME)



RN 423174-01-0 CAPLUS


CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-(1-piperazinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 423174-03-2 CAPLUS

CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-(1-
piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 423174-05-4 CAPLUS
CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-(1-piperazinyl)-, hydrochloride
(9CI) (CA INDEX NAME)




●x HCl

RN 423174-17-8 CAPLUS
CN 1H-Indole, 4-[4-(phenylmethyl)-1-piperazinyl]-1-(phenylsulfonyl)- (9CI)
(CA INDEX NAME)




RN 423174-25-8 CAPLUS

CN 1H-Indole, 1-[(2-bromophenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]-
(9CI) (CA INDEX NAME)




RN 423174-33-8 CAPLUS

CN 1H-Indole, 1-[(6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-41-8 CAPLUS

CN 1H-Indole, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 423174-48-5 CAPLUS

CN 1H-Indole, 1-[(4-aminophenyl)sulfonyl]-4-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 423175-40-0 CAPLUS


CN 1H-Indole, 1-[(5-bromo-2-thienyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 423175-41-1 CAPLUS


CN 1H-Indole, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-4-(1-piperazinyl)- (9CI)

(CA INDEX NAME)



RN 423175-42-2 CAPLUS

CN 1H-Indole, 1-[(4-methoxyphenyl)sulfonyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



<10/037,110, claim 1>Page 144

=> d 5 hitstr

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS


IT **393508-47-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(serotonin 5-HT_{2c} agonist-5-HT₆ antagonist combination pharmaceutical,
and therapeutic uses)

RN 393508-47-9 CAPLUS

CN 1H-Indole, 1-(phenylsulfonyl)-4-(1-piperazinyl)-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:.

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

30.88

181.64

STN INTERNATIONAL LOGOFF AT 16:49:57 ON 21 APR 2003